HomeEverythingEducation
Equities & FundsCrypto & Digital AssetsAI & TechnologyBusiness & CorporateUS Politics & PolicyGeopolitics & Global RiskMacro, Rates & FXCommodities & EnergyEuropean Politics & MarketsAsia-PacificReal Estate & Property
Story archiveAll categories
← All Stories

Summit Therapeutics Reports Phase II AK112-206 Trial Data

Created at 5 Jun · 11:59 PM1 source
IN SHORT

Summit Therapeutics has announced data from its Phase II AK112-206 trial. The trial focused on AK112's efficacy in patients diagnosed with non-small cell lung cancer.

✉Newsletter

PiQ Daily

Pick your topics. Get only what matters, on your cadence.

Who's Involved

Summit Therapeutics
Company announcing Phase II trial data

↳ Why This Matters

The announcement of trial data is significant for Summit Therapeutics as it provides crucial information on the potential efficacy of AK112, a key drug candidate, in treating non-small cell lung cancer, which could impact the company's future development and commercialization strategies.

Key facts

  • Summit Therapeutics announced data from its Phase II AK112-206 trial.
  • The trial investigated AK112 in patients with non-small cell lung cancer.

Summit Therapeutics has released data from its Phase II AK112-206 clinical trial. This trial was designed to evaluate the effectiveness of AK112 in patients suffering from non-small cell lung cancer. Further details regarding the specific outcomes and implications of the data were not immediately available in the announcement.

Frequently asked questions

Summit Therapeutics is a biopharmaceutical company focused on developing novel medicines.

AK112 is an investigational drug being tested by Summit Therapeutics.

The trial focused on non-small cell lung cancer.

What Happens Next

01Further details on the AK112-206 trial data are expected.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence

How It Developed

5 Jun · 4:36 PM
Summit Therapeutics announced Phase II AK112-206 trial data investigating AK112 in non-small cell lung cancer patients.
Yahoo News | Finance Top Stories via PiQSuite

Sources

T1
Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Datam.piqsuite.com

Related Stories

SambaNova Systems raises $1B at $11B valuation, names JPMorgan as AI inference partner
8 Jul · 7:45 AM
City Labs launches world's first commercial nuclear-powered satellite
8 Jul · 5:30 PM
Waymo robotaxi stops, alerts police to teens drinking and firing gel beads
8 Jul · 3:46 PM
Lovable in talks to double valuation to $13.2B on $300M funding round
8 Jul · 11:20 PM
Apple to spend $30B on Broadcom chips, expanding Colorado factory
8 Jul · 10:03 AM